|
Serotonergic Pharmacotherapy for Agitation of Dementia Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Serotonergic Pharmacotherapy for Agitation of Dementia conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Serotonergic Pharmacotherapy for Agitation of Dementia Clinical research trials and Serotonergic Pharmacotherapy for Agitation of Dementia medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Serotonergic Pharmacotherapy for Agitation of Dementia. Serotonergic Pharmacotherapy for Agitation of Dementia Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Serotonergic Pharmacotherapy for Agitation of Dementia clinical trial. Test subjects typically obtain the finest healthcare available for their Serotonergic Pharmacotherapy for Agitation of Dementia condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Serotonergic Pharmacotherapy for Agitation of Dementia  Serotonergic Pharmacotherapy for Agitation of Dementia
Serotonergic Pharmacotherapy for Agitation of Dementia
For Condition: Dementia,Dementia, Vascular,Alzheimer Disease
Status: No longer recruiting
Sponsor(s): National Institute of Mental Health (NIMH) ,
Synopsis: This study is a randomized, double-blind, placebo-controlled, fixed dose study currently being conducted on two geropsychiatric units at Western Psychiatric Institute and Clinic. It seeks to evaluate the short-term safety and efficacy of citalopram and perphenazine in the treatment of 112 patients suffering from behavioral disturbances associated with dementia. Findings from this research may directly lead to improved acute pharmacotherapy for psychosis and behavioral problems in patients diagnosed with dementia. Improved treatment of behavioral complications with reduced side effects would reduce excess disability in patients diagnosed with dementia, allowing them to be maintained in the community for greater periods of time.
Details: The principal investigator is conducting an inpatient study at Western Psychiatric Institute and Clinic involving two medications for treatment of emotional and behavioral disturbances that may accompany dementia. In this study, 112 patients will be enrolled for up to 17 days in order to investigate the safety and effectiveness of both medications. Forty-two of these patients will be given a recently FDA-approved antidepressant medication called citalopram and 42 will receive one of our current, usual antipsychotic medications called perphenazine. An additional 28 patients will be given non-active placebo capsules. Which treatment a patient is given during the study will be determined by chance. Findings from this investigation may directly lead to the improvement of symptoms such as: agitation, hostility, suspiciousness, hallucinations, and unusual thoughts. Improved treatment of problematic behaviors and a decrease in medication-associated side effects would enable dementia patients to be cared for in their home environments for longer periods of time.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Meets DSM-IV criteria for diagnosis of dementia of the Alzheimer's type (AD), Vascular dementia (VD), mixed (AD and VD) or dementia NOS (Not Otherwise Specified) - Presents with psychosis or behavioral problems severe enough to endanger the patient's health, well-being or safety, as evidenced by a score of at least 3 (moderate) on one of the Neurobehavioral Rating Scale (NBRS) agitation items (8,11,14) or psychosis items (16,18,20) and are not secondary to physical illness nor amenable to environmental optimization - Able to participate in study evaluations and ingest oral medication - Has next of kin or a guardian available to consent to patient's participation. Exclusion Criteria: - Has an unstable medical illness including significant cardiac (specifically bradycardia with ventricular rate below 50), renal, hepatic, or neurological illness (especially Parkinson's disease) other than dementia - Meets DSM-IV criteria for Delirium upon admission to Western Psychiatric Institute and Clinic - Has been medicated within 4 weeks of protocol admission with fluoxetine or 2 weeks with a monoamine oxidase inhibitor (patients will undergo a monitored psychotropic drug washout prior to entering the protocol) - Is currently being treated with cognitive enhancing drugs (Tacrine or Aricept) or any experimental drug - Has a concurrent diagnosis of schizophrenia, bipolar disorder, or major depression - Has preexisting orthostatic hypotension (with > 20 mmHg change from sitting to standing pressure)
Total Enrollment:
Location and Contact Information:
Overall Study Official:
BrucePollock, Principal Investigator, Western Psychiatric Institute and Clinic
University of Pittsburgh Western Psychiatric Institute and Clinic
Pittsburgh, Pennsylvania, 15213
United States
Additional Information:
Study ID Numbers: IA0014;
Study Start Date:
Record last reviewed: January 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00009204
Other Dementia, Vascular Studies:
1. Nurse Managed Clinic for Dementia Patients and Family Caregivers
2. Montessori-Based Activities for Elderly Persons with Dementia
3. Honolulu Heart Program-Study of Stroke and Dementia
4. Brain Study of Patients with Frontal Lobe Dementia and Parkinsonian Disorders
5. Preventing Cognitive Decline with Alternative Therapies
Related Studies:
Other Dementia, Vascular Clinical Trials
Other Pennsylvania Clinical Trials
Other Pittsburgh Clinical Trials
Serotonergic Pharmacotherapy for Agitation of Dementia
|
|
|
|
|
|
|
|
